C-terminal truncation of GSK-3β enhances its dephosphorylation by PP2A

FEBS Letters

Volumn 591, Issue 7, 2017, Pages 1053-1063

  Jin, Nana ^a   Wu, Yue ^a   Xu, Wen ^a,b   Gong, Cheng Xin ^a,b   Iqbal, Khalid ^b   Liu, Fei ^a,b  

^a NANTONG UNIVERSITY   (China)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; glycogen synthase kinase 3 ; phosphorylation; protein phosphatase 2A; truncation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN BINDING;

AGED; ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; PROTEIN DEPHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; VERY ELDERLY; ANIMAL; AUTOPSY; BRAIN; CHEMISTRY; CONFOCAL MICROSCOPY; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY; PHOSPHORYLATION; POSTMORTEM CHANGE; PROCEDURES; TIME FACTOR; TUMOR CELL LINE; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; AUTOPSY; BLOTTING, WESTERN; BRAIN; CELL LINE, TUMOR; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; HEK293 CELLS; HELA CELLS; HUMANS; MALE; MICROSCOPY, CONFOCAL; MUTATION; PHOSPHORYLATION; POSTMORTEM CHANGES; PROTEIN BINDING; PROTEIN PHOSPHATASE 2; SERINE; TIME FACTORS;

EID: 85016475088     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.12617     Document Type: Article

References (45)

1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS and Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084–6089.
2. Lee VM, Balin BJ, Otvos L Jr and Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251, 675–678.
3. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM and Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913–4917.
4. Alonso AC, Grundke-Iqbal I and Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2, 783–787.
5. Alonso AC, Zaidi T, Grundke-Iqbal I and Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91, 5562–5566.
6. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I and Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 98, 6923–6928.
7. Alafuzoff I, Iqbal K, Friden H, Adolfsson R and Winblad B (1987) Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 74, 209–225.
8. Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631–639.
9. Riley KP, Snowdon DA and Markesbery WR (2002) Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51, 567–577.
10. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S et al. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4, 1077–1086.
11. Liu F, Iqbal K, Grundke-Iqbal I and Gong CX (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530, 209–214.
12. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T et al. (2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275, 41340–41349.
13. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R and Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27–39.
14. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J and Hernandez F (2006) Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27, 1258–1268.
15. Perez M, Hernandez F, Lim F, Diaz-Nido J and Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5, 301–308.
16. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VM et al. (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110, 547–556.
17. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102, 6990–6995.
18. Goni-Oliver P, Avila J and Hernandez F (2009) Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J Neurosci Res 87, 1156–1161.
19. Jin N, Yin X, Yu D, Cao M, Gong CX, Iqbal K, Ding F, Gu X and Liu F (2015) Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Sci Rep 5, 8187.
20. Goni-Oliver P, Lucas JJ, Avila J and Hernandez F (2007) N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282, 22406–22413.
21. Ma S, Liu S, Huang Q, Xie B, Lai B, Wang C, Song B and Li M (2012) Site-specific phosphorylation protects glycogen synthase kinase-3β from calpain-mediated truncation of its N and C termini. J Biol Chem 287, 22521–22532.
22. Sutherland C, Leighton IA and Cohen P (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 (Pt 1), 15–19.
23. Wang QM, Fiol CJ, DePaoli-Roach AA and Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269, 14566–14574.
24. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J and Burgering BM (1998) Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 273, 13150–13156.
25. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789.
26. Chu D, Tan J, Xie S, Jin N, Yin X, Gong CX, Iqbal K and Liu F (2015) GSK-3beta is dephosphorylated by PP2A in a Leu309 methylation-independent manner. J Alzheimers Dis 49, 365–375.
27. Wang Y, Yang R, Gu J, Yin X, Jin N, Xie S, Wang Y, Chang H, Qian W, Shi J et al. (2015) Cross talk between PI3K-AKT-GSK-3beta and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging 36, 188–200.
28. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K and Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56, 70–78.
29. Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, Ramakrishna N and Gong CX (2008) Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 22, 3224–3233.
30. Singh TJ, Zaidi T, Grundke-Iqbal I and Iqbal K (1995) Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett 358, 4–8.
31. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K and Gong CX (2006) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 580, 6269–6274.
32. Hernandez F, Perez M, Lucas JJ, Mata AM, Bhat R and Avila J (2004) Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem 279, 3801–3806.
33. Qian W, Liang H, Shi J, Jin N, Grundke-Iqbal I, Iqbal K, Gong CX and Liu F (2011) Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res 39, 6161–6171.
34. Goedert M, Spillantini MG, Jakes R, Rutherford D and Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519–526.
35. Kosik KS, Orecchio LD, Bakalis S and Neve RL (1989) Developmentally regulated expression of specific tau sequences. Neuron 2, 1389–1397.
36. Wolfe MS (2009) Tau mutations in neurodegenerative diseases. J Biol Chem 284, 6021–6025.
37. Goedert M (2005) Tau gene mutations and their effects. Mov Disord 20 (Suppl 12), S45–S52.
38. Liu F and Gong CX (2008) Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 3, 8.
39. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX and Liu F (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19, 1221–1229.
40. Liu F, Grundke-Iqbal I, Iqbal K and Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942–1950.
41. Goni-Oliver P, Avila J and Hernandez F (2011) Calpain regulates N-terminal interaction of GSK-3beta with 14-3-3zeta, p53 and PKB but not with axin. Neurochem Int 59, 97–100.
42. Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K and Tsuruo T (2000) Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 19, 2652–2661.
43. Liu J, Liu MC and Wang KK (2008) Calpain in the CNS: from synaptic function to neurotoxicity. Sci Signal 1, re1.
44. Braak H and Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16, 271–278; discussion 278–84.
45. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G and Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479–486.